Micro-RNA response to imatinib mesylate in patients with chronic myeloid leukemia

Background Micro-RNAs (miRNAs) control gene expression by destabilizing targeted transcripts and inhibiting their translation. Aberrant expression of miRNAs has been described in many human cancers, including chronic myeloid leukemia. Current first-line therapy for newly diagnosed chronic myeloid leukemia is imatinib mesylate, which typically produces a rapid hematologic response. However the effect of imatinib on miRNA expression in vivo has not been thoroughly examined. Design and Methods Using a TaqMan Low-Density Array system, we analyzed miRNA expression in blood samples from newly diagnosed chronic myeloid leukemia patients before and within the first two weeks of imatinib therapy. Quantitative real-time PCR was used to validate imatinib-modulated miRNAs in sequential primary chronic myeloid leukemia samples (n=11, plus 12 additional validation patients). Bioinformatic target gene prediction analysis was performed based on changes in miRNA expression. Results We observed increased expression of miR-150 and miR-146a, and reduced expression of miR-142-3p and miR-199b-5p (3-fold median change) after two weeks of imatinib therapy. A significant correlation (P<0.05) between the Sokal score and pre-treatment miR-142-3p levels was noted. Expression changes in the same miRNAs were consistently found in an additional cohort of chronic myeloid leukemia patients, as compared to healthy subjects. Peripheral blood cells from chronic phase and blast crisis patients displayed a 30-fold lower expression of miR-150 compared to normal samples, which is of particular interest since c-Myb, a known target of miR-150, was recently shown to be necessary for Bcr-Abl-mediated transformation. Conclusions We found that imatinib treatment of chronic myeloid leukemia patients rapidly normalizes the characteristic miRNA expression profile, suggesting that miRNAs may serve as a novel clinically useful biomarker in this disease.

[1]  George A Calin,et al.  MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. , 2008, Blood.

[2]  D. Bartel,et al.  MicroRNAs Modulate Hematopoietic Lineage Differentiation , 2004, Science.

[3]  J. D'halluin,et al.  Activation of p65 NF-kappaB protein by p210BCR-ABL in a myeloid cell line (P210BCR-ABL activates p65 NF-kappaB). , 1997, Oncogene.

[4]  C. Sawyers,et al.  IκB kinase β inhibition induces cell death in Imatinib-resistant and T315I Dasatinib-resistant BCR-ABL+ cells , 2008, Molecular Cancer Therapeutics.

[5]  D. Bartel.  MicroRNAs: Target Recognition and Regulatory Functions , 2009, Cell.

[6]  Aadel A. Chaudhuri,et al.  Sustained expression of microRNA-155 in hematopoietic stem cells causes a myeloproliferative disorder , 2008, The Journal of experimental medicine.

[7]  D. Tenen,et al.  Cellular myosin heavy chain in human leukocytes: isolation of 5' cDNA clones, characterization of the protein, chromosomal localization, and upregulation during myeloid differentiation. , 1991, Blood.

[8]  U Magrini,et al.  Mutations in MYH9 result in the May-Hegglin anomaly, and Fechtner and Sebastian syndromes. The May-Heggllin/Fechtner Syndrome Consortium. , 2000, Nature genetics.

[9]  Uyen Tran,et al.  MicroRNA control of Nodal signalling , 2007, Nature.

[10]  J. Woodgett,et al.  MLK‐3 activates the SAPK/JNK and p38/RK pathways via SEK1 and MKK3/6. , 1996, The EMBO journal.

[11]  H. Kung,et al.  microRNA-146b inhibits glioma cell migration and invasion by targeting MMPs , 2009, Brain Research.

[12]  B. Calabretta,et al.  Requirement of c-Myb for p210(BCR/ABL)-dependent transformation of hematopoietic progenitors and leukemogenesis. , 2008, Blood.

[13]  S. Weiss,et al.  A cancer cell metalloprotease triad regulates the basement membrane transmigration program. , 2006, Genes & development.

[14]  E. Sontheimer,et al.  Origins and Mechanisms of miRNAs and siRNAs , 2009, Cell.

[15]  Rosa Bernardi,et al.  PML inhibits HIF-1α translation and neoangiogenesis through repression of mTOR , 2006, Nature.

[16]  Klaus Rajewsky,et al.  MicroRNA Control in the Immune System: Basic Principles , 2009, Cell.

[17]  Michaela Scherr,et al.  Expression of the miR-17-92 polycistron in chronic myeloid leukemia (CML) CD34+ cells. , 2007, Blood.

[18]  C. Croce,et al.  A microRNA expression signature of human solid tumors defines cancer gene targets , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[19]  C. Burge,et al.  Most mammalian mRNAs are conserved targets of microRNAs. , 2008, Genome research.

[20]  Shangqin Guo,et al.  MicroRNA-mediated control of cell fate in megakaryocyte-erythrocyte progenitors. , 2008, Developmental cell.

[21]  T. Golub,et al.  MicroRNA expression signatures accurately discriminate acute lymphoblastic leukemia from acute myeloid leukemia , 2007, Proceedings of the National Academy of Sciences.

[22]  Mauro,et al.  Prognostic discrimination among younger patients with chronic granulocytic leukemia: relevance to bone marrow transplantation. , 1985, Blood.

[23]  Rosa Bernardi,et al.  PML inhibits HIF-1alpha translation and neoangiogenesis through repression of mTOR. , 2006, Nature.

[24]  S. Lowe,et al.  A microRNA polycistron as a potential human oncogene , 2005, Nature.

[25]  D. Cortez,et al.  A requirement for NF-kappaB activation in Bcr-Abl-mediated transformation. , 1998, Genes & development.

[26]  O. Witte,et al.  Dissection of signaling pathways and cloning of new signal transducers in tyrosine kinase-induced pathways by genetic selection , 1998, Leukemia.

[27]  Xingbin Hu,et al.  Notch signaling inhibits the growth of the human chronic myeloid leukemia cell line K562. , 2009, Leukemia research.

[28]  C. Croce,et al.  Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[29]  Muller Fabbri,et al.  A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. , 2005, The New England journal of medicine.

[30]  O. Witte,et al.  Dissection of signaling pathways and cloning of new signal transducers in tyrosine kinase-induced pathways by genetic selection , 1999, Leukemia.

[31]  T. Golub,et al.  Distinct microRNA expression profiles in acute myeloid leukemia with common translocations , 2008, Proceedings of the National Academy of Sciences.

[32]  S. Schokrpur,et al.  Expression of microRNA-146 suppresses NF-κB activity with reduction of metastatic potential in breast cancer cells , 2008, Oncogene.

[33]  S. Lowe,et al.  Loss of p53 impedes the antileukemic response to BCR-ABL inhibition. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[34]  H. Horvitz,et al.  MicroRNA expression profiles classify human cancers , 2005, Nature.

[35]  P. Northcott,et al.  MicroRNA-199b-5p Impairs Cancer Stem Cells through Negative Regulation of HES1 in Medulloblastoma , 2009, PloS one.

[36]  Borja Saez,et al.  Down-Regulation of hsa-miR-10a in Chronic Myeloid Leukemia CD34+ Cells Increases USF2-Mediated Cell Growth , 2008, Molecular Cancer Research.

[37]  W. Ritchie,et al.  Predicting microRNA targets and functions: traps for the unwary , 2009, Nature Methods.

[38]  Hugo Naya,et al.  Small RNAs analysis in CLL reveals a deregulation of miRNA expression and novel miRNA candidates of putative relevance in CLL pathogenesis , 2008, Leukemia.

[39]  D. Cortez,et al.  A requirement for NF-κB activation in Bcr–Abl-mediated transformation , 1998 .

[40]  J. Radich,et al.  Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia , 2010, Leukemia.

[41]  R. Ren,et al.  Mechanisms of BCR–ABL in the pathogenesis of chronic myelogenous leukaemia , 2005, Nature Reviews Cancer.

[42]  Jing Wang,et al.  Lymphoproliferative disease and autoimmunity in mice with increased miR-17-92 expression in lymphocytes , 2008, Nature Immunology.

[43]  Aimee L Jackson,et al.  Coordinated regulation of cell cycle transcripts by p53-Inducible microRNAs, miR-192 and miR-215. , 2008, Cancer research.

[44]  The May-HegglinFechtner Syndrome Consortium,et al.  Mutations in MYH9 result in the May-Hegglin anomaly, and Fechtner and Sebastian syndromes , 2000, Nature Genetics.

[45]  D. Baltimore,et al.  NF-κB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses , 2006, Proceedings of the National Academy of Sciences.

[46]  R. Larson,et al.  Studies of the human c-myb gene and its product in human acute leukemias. , 1986, Science.

[47]  M. Caligiuri,et al.  Identification of a gene at 11q23 encoding a guanine nucleotide exchange factor: evidence for its fusion with MLL in acute myeloid leukemia. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[48]  C. Croce,et al.  MicroRNAs in normal and malignant hematopoiesis , 2008, Current opinion in hematology.

[49]  J. D'halluin,et al.  Activation of p65 NF-κB protein by p210BCR – ABL in a myeloid cell line (P210BCR – ABL activates p65 NF-κB) , 1997, Oncogene.